Literature DB >> 19878330

A ferric chloride induced arterial injury model used as haemostatic effect model.

F Møller1, M Tranholm.   

Abstract

A number of experimental bleeding models have been applied to animal models of haemophilia in order to evaluate the acute haemostatic effect of procoagulant compounds. In contrast, in vivo thrombosis models (including the FeCl(3) induced injury model) have mainly been used to study antithrombotic pharmacological intervention. However, as there are limitations to existing bleeding models and as new recombinant FVIII, FIX, and FVIIa variants with increased and prolonged activity are generated there is an increasing need for new and optimized in vivo animal models for testing the efficacy of these haemostatic drug candidates. This led us to look at existing thrombosis models in a new perspective. We have studied the effect of a FeCl(3) induced arterial injury in both F8-KO and F9-KO mice using optimized conditions where exposure to FeCl(3) induces occlusion within 4.2 +/- 0.2 min in wild type mice with a normal coagulation system. In contrast, no occlusion was observed in haemophilic mice providing a therapeutic window in the model making it suitable for pharmacological testing of therapeutic intervention. We demonstrate that replacement therapy with a clinical relevant dose of rFVIII (Advate 20-80 U kg(-1)) and rFIX [(0.75 mg kg(-1) BeneFIX) approximately 50 IU kg(-1)] restored coagulation and normalized the time to occlusion following FeCl(3) induced injury in F8-KO mice and restored coagulation and nearly normalized the time to occlusion in F9-KO mice. In conclusion, we have demonstrated that under optimized conditions the FeCl(3) induced arterial injury model provides a therapeutic window that makes it an useful effect model for evaluation of the haemostatic potential of procoagulant drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878330     DOI: 10.1111/j.1365-2516.2009.02133.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Mechanism of hypocoagulability in proton-irradiated ferrets.

Authors:  Gabriel S Krigsfeld; Alexandria R Savage; Jenine K Sanzari; Andrew J Wroe; Daila S Gridley; Ann R Kennedy
Journal:  Int J Radiat Biol       Date:  2013-06-10       Impact factor: 2.694

2.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Authors:  Henrik Østergaard; Jais R Bjelke; Lene Hansen; Lars Christian Petersen; Anette A Pedersen; Torben Elm; Flemming Møller; Mette B Hermit; Pernille K Holm; Thomas N Krogh; Jørn M Petersen; Mirella Ezban; Brit B Sørensen; Mette D Andersen; Henrik Agersø; Haleh Ahmadian; Kristoffer W Balling; Marie Louise S Christiansen; Karin Knobe; Timothy C Nichols; Søren E Bjørn; Mikael Tranholm
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

3.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

4.  Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice.

Authors:  Kellie R Machlus; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans.

Authors:  Rita Marchi; Bethany L Walton; Colleen S McGary; Feng-Chang Lin; Alice D Ma; Rafal Pawlinski; Nigel Mackman; Robert A Campbell; Jorge Di Paola; Alisa S Wolberg
Journal:  Thromb Haemost       Date:  2012-07-26       Impact factor: 5.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.